Cytek Q1 revenue down 7.6% to $41.5M; net loss widens; FY2025 guidance reduced

Cytek Biosciences, Inc.

Revenue $41.5M (-7.6% YoY); gross margin 49% vs 51%; net loss $11.4M vs $6.2M loss prior year.
Adjusted EBITDA loss $3.3M vs $0.7M loss; cash & securities $265.6M, down $12.3M from Dec 2024.
FY2025 revenue guidance revised to $196-210M (-2% to +5% YoY); prior guidance withdrawn.
Repurchased $10.6M of common stock in Q1; launched Cytek Muse Micro instrument.
Strength in APAC and cell sorters/service business offset by US/EMEA product sales slowdown.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.